SL 0101-1

Cat. No.:	HY-15237		
CAS No.:	77307-50-7		
Molecular Formula:	$C_{25}H_{24}O_{12}$		
Molecular Weight:	516.45		
Target:	Ribosomal S6 Kinase (RSK)		
Pathway:	MAPK/ERK Pathway		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



BIOLOGICAL ACTIVITY

Description	SL 0101-1 (SL0101), a kaempferol glycoside, isolated from the tropical plant F. refracta, is a cell-permeable, selective, reversible, ATP-competitive p90 Ribosomal S6 Kinase (RSK) inhibitor, with an IC_{50} of 89 nM[1]. SL 0101-1 (SL0101) is a selective RSK1/2 inhibitor, with a K_i of 1 μM[2].
IC_{50} & Target	RSK1
In Vitro	SL 0101-1 (SL0101) shows proliferation inhibition in human breast cancer cell line MCF-7 and produces a cell cycle block in G_1 phase[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Mol Cell. 2020 Oct 15;80(2):296-310.e6.
- PLoS Biol. 2022 Jun 1;20(6):e3001653.
- Mol Biol Cell. 2022 Aug 17;mbcE22040118.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Smith JA, et al. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. 2005 Feb 1;65(3):1027-34.

[2]. Yu Li, et al. The Affinity of RSK for Cylitol Analogues of SL0101 Is Critically Dependent on the B-ring C-4'-hydroxy. Chem Commun (Camb). 2020 Mar 10;56(20):3058-3060.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA